within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BB01_Hydroxyzine;
model Hydroxyzine_1 
   extends Pharmacolibrary.Drugs.ATC.N.N05BB01_1;

  annotation(Documentation(
    info ="<html><body><p>Hydroxyzine is a first-generation antihistamine with anticholinergic and sedative properties, primarily used for the treatment of anxiety, pruritus, and as a premedication for anesthesia. It is still widely used and is approved for medical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Bizikova, P, et al., &amp; Olivry, T (2008). Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. <i>Veterinary dermatology</i> 19(6) 348–357. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-3164.2008.00697.x&quot;>10.1111/j.1365-3164.2008.00697.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18980631/&quot;>https://pubmed.ncbi.nlm.nih.gov/18980631</a></p></li><li><p>Simons, FE (2002). H1-antihistamines in children. <i>Clinical allergy and immunology</i> 17 437–464. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12113226/&quot;>https://pubmed.ncbi.nlm.nih.gov/12113226</a></p></li><li><p>Simons, FE, &amp; Simons, KJ (1991). Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. <i>Clinical pharmacokinetics</i> 21(5) 372–393. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199121050-00005&quot;>10.2165/00003088-199121050-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1685361/&quot;>https://pubmed.ncbi.nlm.nih.gov/1685361</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Hydroxyzine_1;
